Almost everyone has heard of leukemia, but most people do not have a good understanding of this complex disease. How can healthcare providers explain the basics of leukemia to their patients?
Researchers sought to find out if flotetuzumab shows activity with an acceptable safety profile in patients with acute myeloid leukemia and primary induction failure or early relapse.
Study authors retrospectively evaluated effect of thymoglobulin addition in RIC and MAC regimens on the cumulative incidence and severity of acute and chronic GVHD, overall survival, and relapse rate in adult AML patients who underwent URD PBSCT.
Among patients with de novo AML, fractionated-dose gemtuzumab ozogamicin does not appear to increase the risk of hepatic VOD/SOS after HSCT.
Investigators of this single-center analysis compare the incidence of CRLF2 rearrangement and IKZF1 deletion in Hispanic/Latino vs non-Hispanic/Latino children with B-cell acute lymphoblastic leukemia (B-ALL).
Researchers compare fractionated busulfan myeloablative conditioning to traditional RIC in elderly patients undergoing allogeneic hematopoietic stem cell transplantation.
A team of investigators prospectively evaluated pediatric patients with ALL to determine the effectiveness of pyridoxine (vitamin B6) plus pyridostigmine therapy for vincristine-induced neurotoxicity.
This review of the guidelines is presented as 6 questions and answers that help direct treatment decision for patients 65 and older with newly diagnosed AML.
A team of researchers identified a lack of standardized practices for treating venous thromboembolism among pediatric patients with acute lymphocytic leukemia.
A team of investigators evaluated the effect of measurable residual disease at time of allogeneic hematopoietic cell transplantation in patients with ALL undergoing transplantation during either first or second complete remission.
Among pediatric patients with relapsed or refractory acute lymphoblastic leukemia, the use of blinatumomab may provide encouraging response rates.
Investigators assessed sodium bicarbonate’s viability as a pharmacologic strategy in mouse models and humans with acute myeloid leukemia.
Investigators aimed to determine whether DPP-4 inhibition reduces the incidence of acute graft-vs-host disease among patients receiving allogeneic HSCT.
A sequenced reduced-intensity conditioning regimen may not improve outcomes for patients with acute myeloblastic leukemia and myelodysplasia after allogeneic stem cell transplantation.
This review of relevant medical literature considers concerns about the cumulative dose, dose rate, and dosing schedule of cytarabine in acute myeloid leukemia (AML).
For patients with acute myeloid leukemia, a total of 4 courses of chemotherapy may improve relapse rates but not overall survival, compared with 3 total courses of treatment.
Investigators estimated the risk for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) related to PARP inhibition.
This post-hoc analysis assessed the incidence and characteristics of bleeding-related adverse events in patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma enrolled in the idelalisib registration trials.
Maintenance therapy with oral azacitidine leads to longer overall survival in older patients with acute myeloid leukemia.
Investigators compared outcomes of chemotherapy conditioning with total body irradiation prior to hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia.
Experts assessed mortality rates linked to allogeneic stem cell transplantation in the past 40 years using data from the European Society for Blood and Marrow Transplantation registry.
Investigators assessed the effectiveness of integrated palliative and oncology care on end-of-life outcomes in patients with acute myeloid leukemia.
The sNDA approval is based on efficacy and safety data from the open-label phase 2 OPTIC trial and 5-year data from the phase 2 PACE trial.
A pediatric treatment-inspired approach may improve outcomes among adolescent and young adult patients with Philadelphia-negative acute lymphoblastic leukemia.
Clinicians are not following guideline recommendations, as prognostic biomarker testing for CLL/SLL remains low and affects treatment selection.
A phase 1 trial demonstrated antitumor activity of liso-cel plus ibrutinib with low rates of grade 3 or higher CRS and neurotoxicity among heavily pretreated patients with CLL/SLL.
The British Society for Haematology released an updated guideline, listing recommendations for the diagnosis and management of hairy cell leukemia and hairy cell variant.
Confirmed undetectable MRD after 12 cycles may result in treatment discontinuation.
Investigators compared clinical outcomes between unfit patients with newly diagnosed AML who were treated with either azacitidine or decitabine.
For younger patients with relapsed or refractory AML, the use of decitabine with venetoclax may be an appropriate salvage therapy, and is comparable to intensive chemotherapy regimens.
Researchers reviewed the challenges and future developments in ICI combination therapies for the treatment of patients with acute myeloid leukemia and myelodysplastic syndromes.
Venetoclax in combination with fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin may benefit patients with treatment-naive or relapsed/refractory acute myeloid leukemia.
Investigators retrospectively assessed whether previous TKI therapy may affect response and survival outcomes in patients with relapsed or refractory acute myeloid leukemia.
Study results suggest that flotetuzumab demonstrates antileukemic activity in patients with primary induction failure and early-relapse acute myeloid leukemia.
Even patients who did not achieve MRD negativity at 1 year had stable or decreasing disease levels.
Open-label, randomized clinical trial sought to determine noninferiority of subcutaneous and IV infusion cytarabine in young adults with AML.
There may be no relapse-free survival or overall survival benefits with posttransplant azaciditine in patients with high-risk AML or MDS.
Study results suggested that the discontinuation of tyrosine kinase inhibitors for chronic myeloid leukemia may be safe, without limiting remission.
Investigators addressed challenges associated with the biology, diagnosis, and current state of treatment for patients with
This approach requires a team-coordinated effort by investigators, patients, and caregivers, as well as genomic and cytogenetic laboratories.
Therapy-related AML after lung cancer is rare, but is associated with poor prognosis.
Most common late effects were endocrine, cardiovascular, respiratory; likelihood of late effects up for those who underwent HSCT.
Researchers report on results with CAR-T therapy in real-world populations of patients with ALL or NHL.
A phase 1b trial found ivosidenib with azacitidine well-tolerated in patients with AML who are ineligible for intensive chemotherapy.
Patients with Philadelphia chromosome-positive ALL were treated with dasatinib and blinatumomab during induction and consolidation therapy — without chemotherapy.
Among patients with AML, maintenance therapy with rhG-CSF plus decitabine led to fewer relapses compared with patients who received no treatment after HSCT.
Investigators aimed to determine and compare outcomes in patients with relapsed or refractory ALL who were treated with anti-CD19 CAR T-cell therapy.
Among patients with acute myeloid leukemia, minimal residual disease-negativity may be linked to improved survival rates.
Venetoclax, a BCL2 inhibitor, used in combination with a HMA improved outcomes in a cohort of 9 patients with AML secondary to MPN.
Researchers evaluated and validated the effectiveness of a 4-factor prognostic model among patients with CLL treated with ibrutinib.
Addition of midostaurin, a first-generation FLT3 inhibitor, to frontline induction therapy is currently a standard approach to the treatment of FLT3-mutated AML.